Chimeric antigen receptor T cell immunotherapy for refractory and relapsed acute lymphoblastic leukemia: Challenge and Countermeasures
10.3760/cma.j.cn114452-20220302-00111
- VernacularTitle:嵌合抗原受体-T细胞免疫治疗难治/复发急性淋巴细胞白血病的挑战与对策
- Author:
Yingjun CHANG
1
;
Xiangyu ZHAO
Author Information
1. 北京大学人民医院血液科，北京大学血液病研究所，国家血液系统疾病临床医学研究中心，造血干细胞移植治疗血液病北京市重点实验室，北京100044
- Keywords:
Immunotherapy, adoptive;
Chimeric antigen receptor T cell;
Refractory and relapsed acute lymphoblastic leukemia;
Leukemia relapse;
Immune rejection;
Measur
- From:
Chinese Journal of Laboratory Medicine
2022;45(8):777-782
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor(CAR)-T cell immunotherapy for refractory and relapsed acute lymphoblastic leukemia (R/R ALL) is one of the breakthroughs in the field of hematological malignant disease treatment. However, several challenges remain, such as immune rejection of allogeneic CAR-T cells, leukemia relapse, as well as could we apply CAR-T cell immunotherapy to ALL patients with positive measurable residual disease and those of newly diagnosed cases. The safety and efficiency of CAR-T therapy will be further improved for patients with ALL only by establishing appropriate strategies to address these challenges.
